You are here

Article Text

Article menu

Download PDFPDF

Abstracts
2.3 ISCHEMIC – Treatment
P146/118  NeVa ONE registry interim analysis: recanalization outcomes from a large, real-world patient cohort
Free
  1. Pervinder Bhogal1,
  2. José Díaz2,
  3. José Ignacio Gallego3,
  4. Marta Seoane Dopico4,
  5. Johannes Pfaff5,
  6. Daniel Behme6,
  7. Gulielmo Pero7,
  8. Maurits Voormolen8,
  9. Seby John9,
  10. Nicolás Augusto Romero Flórez10,
  11. Salvador Miralbes Celma11,
  12. Tom de Waele12,
  13. Olivier Francois13,
  14. Enrico Cotroneo14,
  15. Geert Maleux15
  1. 1Royal London Hospital, London, UK
  2. 2Virgen of Arrixaca University Clinical Hospital, El Palmar, Spain
  3. 3General University Hospital of Alicante, Alacant, Spain
  4. 4[CHUAC] University Hospital of A Coruña, A Coruña, Spain
  5. 5Christian Doppler Klinik, Salzburg, Austria
  6. 6Otto-von-Guericke-University Magdeburg, Magdeburg, Germany
  7. 7ASST Great Metropolitan Niguarda, Milano, Italy
  8. 8Antwerp University Hospital, Edegem, Belgium
  9. 9Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
  10. 10Hospital Parc Taulí de Sabadell, Sabadell, Spain
  11. 11Hospital Universitari Son Espases, Palma, Spain
  12. 12Onze Lieve Vrouwziekenhuis, Aalst, Belgium
  13. 13AZ Groeninge, Kortrijk, Belgium
  14. 14San Camillo Forlanini Hospital, Roma, Italy
  15. 15UZ Leuven, Leuven, Belgium

Abstract

Introduction The NeVa stent retriever has proven it’s safety and performance for treating large vessel occlusion (LVO) in acute ischemic stroke (AIS) across multiple clinical studies including the most recently published CLEAR Trial. This trial was conducted under rigorous scrutiny, with independent boards adjudicating outcomes. Real-world data is helpful in assessing the reproducibility of patient outcomes.

Aim of Study NeVa ONE is a multicenter, international, prospective registry designed to assess outcomes in a real-world cohort of patients.

Methods AIS LVO patients treated with NeVa either as first-line or as a rescue device are included. This interim analysis reports performance results of 175 subjects from 15 centers in 7 countries treated with NeVa used as first-line device. Study endpoints are successful (TICI2b-3) and/or complete (TICI 2c-3) recanalization at first pass (mFPE/FPE), up to three passes, and at procedure end. Secondary endpoints include neurological deterioration at 24 hours and device/procedure-related adverse events.

Results Mean patient age was 71±14 years. Most frequently reported conditions in medical history included: Hypertension (39%); Dyslipidemia (19%); Diabetes (14%) and Atrial Fibrillation (14%). Median admission-NIHSS was 16 (IQR:12–20). IV-tPA was administered in 43,1% of subjects. Occlusion sites were: ICA (23%), MCA (71%), posterior circulation (5%), and ACA (1%). Recanalization rates were: mFPE: 72.6%; FPE: 58.3%; ≤3pass eTICI 2b-3: 90.9%; ≤3pass eTICI 2c-3: 76.0%; Final eTICI 2b-3: 98.9% and final eTICI 2c-3: 83.4%.

Conclusion NeVa ONE Registry represents real-world data obtained from LVO AIS subjects treated with NeVa.

Disclosure of Interest Nothing to disclose

http://dx.doi.org/10.1136/jnis-2023-ESMINT.174

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.